AU509445B2 - Phathalanes - Google Patents

Phathalanes

Info

Publication number
AU509445B2
AU509445B2 AU21073/77A AU2107377A AU509445B2 AU 509445 B2 AU509445 B2 AU 509445B2 AU 21073/77 A AU21073/77 A AU 21073/77A AU 2107377 A AU2107377 A AU 2107377A AU 509445 B2 AU509445 B2 AU 509445B2
Authority
AU
Australia
Prior art keywords
phathalanes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU21073/77A
Other languages
English (en)
Other versions
AU2107377A (en
Inventor
A. S Bones O K. P. and Tuft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
Kefalas AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9722860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU509445(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kefalas AS filed Critical Kefalas AS
Publication of AU2107377A publication Critical patent/AU2107377A/en
Application granted granted Critical
Publication of AU509445B2 publication Critical patent/AU509445B2/en
Assigned to H. LUNDBECK A/S reassignment H. LUNDBECK A/S Alteration of Name(s) in Register under S187 Assignors: KEFALAS A/S
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU21073/77A 1976-01-14 1977-01-05 Phathalanes Expired AU509445B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1486/76A GB1526331A (en) 1976-01-14 1976-01-14 Phthalanes
GBGB1486/76 1976-01-14

Publications (2)

Publication Number Publication Date
AU2107377A AU2107377A (en) 1978-07-13
AU509445B2 true AU509445B2 (en) 1980-05-15

Family

ID=9722860

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21073/77A Expired AU509445B2 (en) 1976-01-14 1977-01-05 Phathalanes

Country Status (19)

Country Link
US (1) US4136193A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS52105162A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT359488B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU509445B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE850401A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1094087A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (3) CH626886A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2657013C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK143275C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES454980A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI63754C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2338271A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1526331A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE44055B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (2) NL192451C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO147243C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ183001A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE429551B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA7757B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
AU6776196A (en) * 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response
ATE205824T1 (de) 1997-07-08 2001-10-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
DK1042310T3 (da) * 1997-11-11 2002-12-02 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
AU746665B2 (en) 1998-10-20 2002-05-02 H. Lundbeck A/S Method for the preparation of citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
HRP20010418A2 (en) 1998-12-08 2002-06-30 Lundbeck & Co As H Benzofuran derivatives, their preparation and use
DK1140886T3 (da) 1998-12-23 2003-07-28 Lundbeck & Co As H Fremgangsmåde til fremstilling af 5-cyanophtalid
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
KR100604156B1 (ko) * 1999-04-14 2006-07-25 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조방법
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991486A1 (it) * 1999-07-06 2001-01-06 Vis Farmaceutici S P A Processo per la sintesi di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB2360281B (en) 1999-10-25 2002-01-16 Lundbeck & Co As H Method for the preparation of citalopram
IL143875A0 (en) 1999-10-25 2002-04-21 Lundbeck & Co As H Method for the preparation of citalopram
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
US6310222B1 (en) * 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
PL355532A1 (en) * 1999-12-28 2004-05-04 H.Lundbeck A/S Method for the preparation of citalopram
CN1211377C (zh) * 1999-12-30 2005-07-20 H.隆德贝克有限公司 西酞普兰的制备方法
EP1254129B1 (en) * 2000-01-14 2003-10-22 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
US6433196B1 (en) 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
IES20010143A2 (en) * 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
NL1017415C1 (nl) * 2000-02-24 2001-05-18 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
NL1017417C1 (nl) * 2000-03-03 2001-03-16 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
JP2003527387A (ja) 2000-03-13 2003-09-16 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
AU2001239210A1 (en) * 2000-03-13 2001-09-24 H. Lundbeck A/S Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
DK1265882T3 (da) 2000-03-14 2004-06-01 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
AU2001244086A1 (en) * 2000-03-16 2001-09-24 H. Lundbeck A/S Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
KR100821912B1 (ko) * 2000-05-12 2008-04-16 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
AR032455A1 (es) * 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
CA2383963A1 (en) * 2000-07-06 2002-01-17 Eva Bolzonella Method for the preparation of citalopram
HRP20030053A2 (en) * 2000-07-21 2005-02-28 H. Lundbeck A/S Novel compounds and their use as glycine transport inhibitors
CA2353693C (en) * 2000-08-10 2003-07-22 H. Lundbeck A/S Pharmaceutical composition containing citalopram
IL144817A0 (en) * 2000-08-18 2002-06-30 Lundbeck & Co As H Method for the preparation of citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
IT1319686B1 (it) * 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
SK286283B6 (sk) * 2000-12-22 2008-06-06 H. Lundbeck A/S Spôsob výroby čisteného citalopramu
DK1181272T3 (da) * 2000-12-28 2002-12-30 Lundbeck & Co As H Fremgangsmåde til fremstilling af rent citalopram
DE10112828C1 (de) * 2000-12-28 2002-11-21 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
DE10164725B4 (de) * 2000-12-28 2004-08-26 H. Lundbeck A/S Verfahren zur Herstellung von gereinigtem Citalopram
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
CA2435925A1 (en) * 2001-01-30 2002-08-08 Orion Corporation Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
US20040133017A1 (en) * 2001-02-22 2004-07-08 Pulla Reddy Muddasani Process for the preparation of citalopram
GB0105627D0 (en) 2001-03-07 2001-04-25 Cipla Ltd Preparation of phthalanes
CA2439856A1 (en) * 2001-03-09 2002-09-19 Swargam Sathyanarayana Process for the preparation of citalopram
HRP20030744A2 (en) * 2001-05-01 2005-06-30 H. Lundbeck A/S The use of enantiomeric pure escitalopram
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IN192057B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd
KR20040028947A (ko) * 2001-07-31 2004-04-03 하. 룬트벡 아크티에 셀스카브 에시탈로프람 함유 결정 조성물
EP1288211A1 (en) * 2001-08-28 2003-03-05 Sekhsaria Chemicals Ltd. Improved process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US6967259B2 (en) * 2001-09-24 2005-11-22 Pharmachem Technologies Limited Process for the preparation of Citalopram intermediate
NZ532033A (en) * 2001-10-12 2006-11-30 Azevan Pharmaceuticals Inc 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives as vasopressin V1a receptor antagonists
IN192863B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2001-11-13 2004-05-22 Ranbaxy Lab Ltd
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
WO2003057132A2 (en) * 2002-01-07 2003-07-17 Sun Pharmaceutical Industries Limited Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
GB2385848A (en) * 2002-02-27 2003-09-03 Cipla Ltd Citalopram salts
GB2387844B (en) * 2002-02-27 2005-05-11 Matrix Lab Ltd Separation of impurities from a crude mixture of citalopram
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
WO2003080558A1 (fr) * 2002-03-27 2003-10-02 Bando Chemical Industries, Ltd. Nouveau 1,3,5-tris(arylamino)benzène
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
TWI306846B (en) * 2002-08-12 2009-03-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
WO2004016602A1 (en) * 2002-08-14 2004-02-26 Natco Pharma Limited Process for the preparation of high purity citalopram and its pharmaceutically acceptable salts
GB2385051B (en) * 2002-08-29 2003-12-24 Max India Ltd Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
PL378275A1 (pl) * 2002-12-23 2006-03-20 H. Lundbeck A/S Bromowodorek escitalopramu i sposób jego wytwarzania
WO2004065375A1 (en) * 2003-01-17 2004-08-05 Natco Pharma Limited Processes for the preparation of escitalopram and its precursor
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
ITMI20030479A1 (it) * 2003-03-13 2004-09-14 Adorkem Technology S P A Procedimento per la preparazione di un ciano-isobenzofurano.
US7019153B2 (en) * 2003-06-10 2006-03-28 Sun Pharmaceutical Industries Limited Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
GB0317475D0 (en) * 2003-07-25 2003-08-27 Meditab Specialities Pvt Ltd Product
ITFI20030202A1 (it) * 2003-07-28 2005-01-29 Synteco Spa Processo per la preparazione di derivati del
NZ545836A (en) * 2003-09-17 2009-09-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
EP1678122A4 (en) * 2003-10-28 2007-05-23 Wockhardt Ltd IMPROVED PROCESS FOR THE PREPARATION OF CITALOPRAM HYDROBROMIDE
DK1506963T3 (da) * 2003-10-28 2005-08-01 Adorkem Technology Spa Fremgangsmåde til fremstilling af citalopram
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US20080119662A1 (en) * 2004-02-16 2008-05-22 Jubilant Organosys Limted One Spot Synthesis of Citalopram from 5-Cyanophthalide
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) * 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
EP2141156A1 (en) 2004-08-23 2010-01-06 Sun Pharma Global FZE Process for Preparation of Citalopram and Enantiomers
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
WO2006103550A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Processes for the preparation of citalopram and its intermediate 5-aminophthalide
EP1871358A1 (en) * 2005-04-22 2008-01-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
PE20070093A1 (es) * 2005-04-22 2007-02-07 Wyeth Corp Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
AR056980A1 (es) 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
WO2007008758A2 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
JP5328349B2 (ja) * 2005-07-19 2013-10-30 アゼヴァン ファーマスーティカルズ，インコーポレイテッド ベータ−ラクタミルフェニルアラニン、システイン、およびセリン・バソプレッシン拮抗剤
EA200800360A1 (ru) * 2005-07-22 2008-06-30 Мириад Дженетикс, Инк. Формуляции с высоким содержанием лекарства и дозированные формы
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN101309924A (zh) * 2005-11-14 2008-11-19 H.隆德贝克有限公司 依地普仑的制备方法
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
RU2008135326A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249435A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP4927497B2 (ja) * 2006-10-25 2012-05-09 株式会社シスコ 無湿乾燥用ホッパー装置
CN100457747C (zh) * 2006-11-21 2009-02-04 浙江大学 抗抑郁药西酞普兰关键中间体5-氰基苯酞的制备工艺
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
US7566793B2 (en) * 2007-04-23 2009-07-28 Synthon Bv Process for resolving citalopram
KR20100028559A (ko) * 2007-05-18 2010-03-12 시플라 리미티드 데스메틸시탈로프람을 경유한 에스시탈로프람의 제조방법, 상기 ｓ-이성체의 광학분리 및 메틸화
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US8022232B2 (en) * 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20100087664A1 (en) * 2008-10-07 2010-04-08 Ravindra Vedantham Preparation of citalopram and salts thereof
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2491038B1 (en) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
ES2662350T3 (es) 2010-07-01 2018-04-06 Azevan Pharmaceuticals, Inc. Procedimientos para el tratamiento del trastorno por estrés postraumático
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
WO2013110313A1 (en) * 2012-01-23 2013-08-01 H. Lundbeck A/S Selective allosteric modulators of the serotonin transporter
SG10202001065SA (en) 2014-03-28 2020-04-29 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
EP4091634A1 (en) 2016-03-10 2022-11-23 Janssen Pharmaceutica NV Methods of treating depression using orexin-2 receptor antagonists
CA3075759A1 (en) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
AU2020316013A1 (en) 2019-07-19 2022-02-17 Arx, Llc Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1965-03-18

Also Published As

Publication number Publication date
CH626886A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-12-15
NL192451B (nl) 1997-04-01
NL970031I1 (nl) 1997-10-01
NL7700244A (nl) 1977-07-18
FI63754C (fi) 1983-08-10
GB1526331A (en) 1978-09-27
AT359488B (de) 1980-11-10
DK13177A (da) 1977-07-15
DK143275B (da) 1981-08-03
FI63754B (fi) 1983-04-29
NZ183001A (en) 1978-06-02
FR2338271B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-11-05
ATA947276A (de) 1980-04-15
DE2657013C2 (de) 1985-11-14
DE2657013A1 (de) 1977-07-28
FI770073A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1977-07-15
NL970031I2 (nl) 1997-10-01
IE44055L (en) 1977-07-14
DK143275C (da) 1982-01-18
FR2338271A1 (fr) 1977-08-12
AU2107377A (en) 1978-07-13
SE7614201L (sv) 1977-07-15
CA1094087A (en) 1981-01-20
IE44055B1 (en) 1981-07-29
SE429551B (sv) 1983-09-12
NO147243C (no) 1983-03-02
JPS6135986B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1986-08-15
US4136193A (en) 1979-01-23
NO1996001I1 (no) 1996-01-05
ES454980A1 (es) 1978-04-01
CH632258A5 (de) 1982-09-30
ZA7757B (en) 1977-11-30
NO147243B (no) 1982-11-22
BE850401A (fr) 1977-07-14
CH632259A5 (de) 1982-09-30
NO770109L (no) 1977-07-15
JPS52105162A (en) 1977-09-03
NL192451C (nl) 1997-08-04

Similar Documents

Publication Publication Date Title
AU509445B2 (en) Phathalanes
AU2329877A (en) Hentriakontapeptides
AU508246B2 (en) E-2-propynyl-benzylamines
AU5728680A (en) 1-oxadethia-cephalosporins
AU2268977A (en) 3-Phenyl-2-Oxazolidinones
AU2676477A (en) Surf-Ski
AU2696477A (en) Pipejoint
AU2401277A (en) Trans-hexahydro-pyrido-indoles
AU2838577A (en) Perhydro-aza-heterocycles
AU2372777A (en) Amidinoureas
AU2694177A (en) 7-b-oxyiminoacylcephalosporins
AU2464877A (en) Aminopiperidines
AU2921577A (en) Methanisation
AU2765177A (en) N-sulphenylated oxime-carbamates
AU2537677A (en) Aryltrifluoroethylamines
AU2543477A (en) 1-ARYLOXY-2-HYDROXY-3-AMINOPROPANeS
AU2915477A (en) Corticods
AU2228277A (en) 3-deoxyanthocyanidins
AU2421077A (en) Benzoylethers
AU2912577A (en) 1-amino-2-hydroxy-3-heterocycloxy-propanes
AU2920677A (en) Imidazo-isoquinolines
AU2556877A (en) Substicuted 2-vinyl-chromones
AU2516177A (en) Isoindols
AU2428577A (en) Bis-pencillanoyloxy-alkanes
AU2581877A (en) Neoviridogriseins